Immunocore Holdings plc (IMCR)
IMCR Stock Price Chart
Explore Immunocore Holdings plc interactive price chart. Choose custom timeframes to analyze IMCR price movements and trends.
IMCR Company Profile
Discover essential business fundamentals and corporate details for Immunocore Holdings plc (IMCR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Feb 2021
Employees
493.00
Website
https://www.immunocore.comCEO
Bahija Jallal
Description
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
IMCR Financial Timeline
Browse a chronological timeline of Immunocore Holdings plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.01, while revenue estimate is $146.88m.
Earnings released on 6 May 2026
EPS came in at $0.25 surpassing the estimated -$0.26 by +196.15%, while revenue for the quarter reached $145.02m , missing expectations by -0.28%.
Earnings released on 25 Feb 2026
EPS came in at -$0.60 falling short of the estimated -$0.28 by -114.29%, while revenue for the quarter reached $140.05m , missing expectations by -3.07%.
Earnings released on 6 Nov 2025
EPS came in at $0.02 surpassing the estimated -$0.30 by +105.19%, while revenue for the quarter reached $103.69m , missing expectations by -27.09%.
Earnings released on 7 Aug 2025
EPS came in at -$0.20 surpassing the estimated -$0.21 by +4.76%, while revenue for the quarter reached $134.35m , beating expectations by +0.08%.
Earnings released on 7 May 2025
EPS came in at $0.10 surpassing the estimated -$0.35 by +128.57%, while revenue for the quarter reached $121.45m , missing expectations by -0.25%.
Earnings released on 26 Feb 2025
EPS came in at -$0.47 falling short of the estimated -$0.31 by -51.61%, while revenue for the quarter reached $105.16m , beating expectations by +23.01%.
Earnings released on 6 Nov 2024
EPS came in at $0.17 surpassing the estimated -$0.35 by +148.57%, while revenue for the quarter reached $107.40m , missing expectations by -2.34%.
Earnings released on 8 Aug 2024
EPS came in at -$0.23 surpassing the estimated -$0.45 by +48.89%, while revenue for the quarter reached $95.43m , beating expectations by +0.29%.
Earnings released on 8 May 2024
EPS came in at -$0.49 falling short of the estimated -$0.33 by -48.48%, while revenue for the quarter reached $88.49m , missing expectations by -0.24%.
Earnings released on 28 Feb 2024
EPS came in at -$0.40 falling short of the estimated -$0.28 by -42.86%, while revenue for the quarter reached $133.52m , beating expectations by +57.21%.
Earnings released on 7 Nov 2023
EPS came in at $0.04 surpassing the estimated -$0.32 by +112.50%, while revenue for the quarter reached $76.17m , missing expectations by -7.25%.
Earnings released on 10 Aug 2023
EPS came in at -$0.37 surpassing the estimated -$0.40 by +7.50%, while revenue for the quarter reached $76.59m , beating expectations by +2.62%.
Earnings released on 10 May 2023
EPS came in at -$0.43 falling short of the estimated -$0.30 by -43.33%, while revenue for the quarter reached $68.05m , missing expectations by -7.68%.
Earnings released on 1 Mar 2023
EPS came in at -$0.63 falling short of the estimated -$0.00 by -185.19k%, while revenue for the quarter reached $59.07m , missing expectations by -5.43%.
Earnings released on 9 Nov 2022
EPS came in at $0.14 surpassing the estimated -$0.26 by +153.85%, while revenue for the quarter reached $45.58m , beating expectations by +4.48%.
Earnings released on 10 Aug 2022
EPS came in at -$0.17 surpassing the estimated -$0.72 by +76.39%, while revenue for the quarter reached $38.85m , beating expectations by +52.54%.
Earnings released on 11 May 2022
EPS came in at -$0.48 surpassing the estimated -$1.07 by +55.14%, while revenue for the quarter reached $29.48m , missing expectations by -0.60%.
Earnings released on 3 Mar 2022
EPS came in at -$1.21 falling short of the estimated -$1.08 by -12.04%, while revenue for the quarter reached $8.89m , missing expectations by -14.95%.
Earnings released on 10 Nov 2021
EPS came in at -$0.93 falling short of the estimated -$0.85 by -9.41%, while revenue for the quarter reached $8.00m , missing expectations by -11.42%.
Earnings released on 11 Aug 2021
EPS came in at -$1.04 falling short of the estimated -$0.95 by -9.47%, while revenue for the quarter reached $7.92m , missing expectations by -27.67%.
IMCR Stock Performance
Access detailed IMCR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
